Allegro

Allegro is a Belgian life sciences company founded in 2021, specializing in the development of breakthrough biomedical technologies at the intersection of biotech, engineering, and medtech. The company's lead innovations include a proprietary platform targeting chronic degenerative diseases—especially osteoarthritis—using injectable nanotechnology to restore synovial fluid function and custom-engineered regenerative meniscus cartilage. Recognized as a Top 10 Biotech Company by LifeSciences Review in late 2023, Allegro has inaugurated state-of-the-art R&D facilities in Liège, Belgium. Its pipeline addresses major unmet needs in rheumatology and orthopedics with an emphasis on patient-centric design.